Serum markers of fibrosis, cardiovascular and all-cause mortality in hemodialysis patients: the AURORA trial.

ABSTRACT:

Background

Biomarkers of fibrosis are associated with outcome in several cardiovascular diseases. However, their relevance to chronic kidney disease and dialysis is uncertain, as it remains unclear how the kidneys and the dialysis procedure itself affect their elimination and degradation. We aimed to investigate the relationship of the blood levels of two markers associated with fibrosis: procollagen type I C-terminal pro-peptide (PICP) and galectin-3 (Gal-3) with mortality in dialysis patients.

Methods

Procollagen type I C-terminal pro-peptide and galectin-3 were measured at baseline in 2773 patients enrolled in the AURORA trial, investigating the effect of rosuvastatin on cardiovascular outcomes, in patients on hemodialysis, and their interaction with CV death or all-cause

SUBMITTER: Salib M 

PROVIDER: S-EPMC9151553 | biostudies-literature | 2022 Jun

REPOSITORIES: biostudies-literature